7145-61-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-6-(methylthio)pyridazine is used as a building block for the synthesis of various pharmaceuticals. Its mild, efficient, and selective reactivity makes it a valuable compound in the development of new drugs and medicinal products.
Used in Agrochemical Industry:
3-Chloro-6-(methylthio)pyridazine is also utilized as a building block in the synthesis of agrochemicals. Its unique chemical properties contribute to the development of effective and selective pesticides and other agricultural chemicals.
Used in Organic Synthesis:
3-Chloro-6-(methylthio)pyridazine serves as a key intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Used as a Reagent in Chemical Research:
Due to its selective reactivity, 3-Chloro-6-(methylthio)pyridazine is employed as a reagent in chemical research, facilitating the exploration of new chemical processes and the development of innovative products.
It is important to handle 3-Chloro-6-(methylthio)pyridazine with care, as it may pose potential hazards and toxicity. Proper safety measures should be taken during its use and manipulation to ensure the well-being of individuals and the environment.

InChI:InChI=1/C5H5ClN2S/c1-9-5-3-2-4(6)7-8-5/h2-3H,1H3

Upstream product

• 3916-78-7 6-chloro-3(2H)-pyridazinethione 
• 74-88-4 methyl iodide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 3916-78-7 3-mercapto-6-chloropyridazine 
• 40954-07-2 6-Chloro-3-methylthiopyridazine-1-oxide 
• 141-30-0 3,6-dichlorpyridazine 
• 5188-07-8 sodium thiomethoxide 
• 74-93-1 methylthiol 

Downstream Products

• 59019-09-9 3-methylsulfanyl-6-phenoxy-pyridazine 
• 7145-62-2 3-chloro-6-(methylsulfonyl)pyridazine 
• 100224-59-7 3-[3,6-dihydro-4-(3-methylphenyl)-1(2 H)-pyridinyl]-6-(methylthio)pyridazine 

Relevant academic research and scientific papers

Synthesis of novel 3-allylseleno-6-alkylthiopyridazines: Their anticancer activity against MCF-7 cells

A new series of 3-allylseleno-6-alkylthiopyridazines 6a-6g was synthesized by two synthetic routes from 3,6-dichloropyridazine to develop new anticancer agents. These new compounds showed antiproliferative activities against breast cancer (MCF-7) cells in CCK-8 assays, and could be promising candidates for chemotherapy of carcinomas. Compound 6e (3-allylseleno-6-pentylthiopyridazine) showed higher potency than 5FU for inhibiting the growth of these cell lines. This suggests the potential anticancer activity of compound 6e.

Synthesis and Evaluation of Novel 3-Allylseleno-6-Alkylsulfonylpyridazine Derivatives with Potential Anticancer Properties

A new series of 3-allylseleno-6-alkylsulfonylpyridazines and 3-allylseleno-6-alkylsulfinylpyridazines were synthesized from 3,6-dichloropyridazine for anticancer agent development. The inhibitory effects of 3-allylseleno-6-alkylsulfonylpyridazines on human cancer cell lines were investigated. The synthesis involved thiolation, oxidation, selenylation, and Se-allylation of alkylthiols. That is, sodium methanethiolate, ethanethiol, propanethiol, butanethiol, pentanethiol, and hexanethiol were inserted into the 6-position of the pyridazine nucleus. These new synthetic compounds exhibited antiproliferative activity against human breast cancer (MCF-7), hepatocarcinoma (Hep3B), and human colon carcinoma (RKO) cells in CCK-8 assays, and are potential candidates for cancer chemotherapy.

Tetrazine-mediated bioorthogonal prodrug-prodrug activation

The selective and biocompatible activation of prodrugs within complex biological systems remains a key challenge in medical chemistry and chemical biology. Herein we report, for the first time, a dual prodrug activation strategy that fully satisfies the principle of bioorthogonality by the symbiotic formation of two active drugs. This dual and traceless prodrug activation strategy takes advantage of the INVDA chemistry of tetrazines (here a prodrug), generating a pyridazine-based miR21 inhibitor and the anti-cancer drug camptothecin and offers a new concept in prodrug activation.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

NOVEL PHENYLPYRROLE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula -V-NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].

OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Methylathion of Heterocyclic Compounds Containing NH, SH and/or OH Groups by Means of N,N-Dimethylformamide Dimethyl Acetal

Methylations of heterocyclic systems, such as benzimidazole, naphthimidazole, imidazopyridine, purine, pyridine, pyrimidine, pyridazine and s-triazolopyridazine, which bore SH, NH and/or OH groups, were carried out with dimethylformamide dimethyl acetal to give the corresponding S-, N- and/or O-methyl derivatives in high yields.Selective methylation of some compounds containing both SH and NH groups took place to give first the S-methyl and subsequently the S,N-dimethyl derivatives.No side reactions, such as C-methylation, were observed.